Martina Frassineti

TL;DR: The results indicate that disease-associated mutant G2019S LRRK2 impairs DRD1 internalization, leading to an alteration in signal transduction, and the mutant forms of L RRK2 affect receptor turnover by decreasing the rate of DRD2 trafficking from the Golgi complex to the cell membrane.

TL;DR: Results suggest that the second-generation antipsychotic olanzapine, through the inhibition of DDO activity, increases L-glutamate release in the PFC of treated mice.

TL;DR: The efficacy of two novel, potent and chemically distinct NOP receptor agonists, AT‐390 and AT‐403, to improve Parkinsonian disabilities and attenuate dyskinesia development and expression are investigated.

TL;DR: The G2019S mutation unravels a dopamine‐promoting action of LRRK2 inhibitors while blunting their effects on glutamate release, which highlights their positive potential for the treatment of PD, especially of L RRK2 mutation carriers.